Cargando…
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma
Purpose: To evaluate the safety and ocular hypotensive efficacy of 4 trabodenoson doses administered twice daily over 14 or 28 days in subjects with ocular hypertension or primary open-angle glaucoma (POAG). Methods: In this multicenter, randomized, double-masked, placebo-controlled, dose-escalation...
Autores principales: | Myers, Jonathan S., Sall, Kenneth N., DuBiner, Harvey, Slomowitz, Natanya, McVicar, William, Rich, Cadmus C., Baumgartner, Rudolf A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069706/ https://www.ncbi.nlm.nih.gov/pubmed/27002298 http://dx.doi.org/10.1089/jop.2015.0148 |
Ejemplares similares
-
A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers
por: Laties, Alan, et al.
Publicado: (2016) -
Late-day intraocular pressure–lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial
por: DuBiner, Harvey B, et al.
Publicado: (2014) -
Topical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION)
por: Guo, Yan, et al.
Publicado: (2019) -
Fixed-combination brinzolamide 1%/brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies
por: Realini, T, et al.
Publicado: (2013) -
Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery
por: Kim, Terry, et al.
Publicado: (2018)